Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.

Coelho, TeresaDispenzieri, AngelaGrogan, MarthaConceição, IsabelWaddington-Cruz, MárciaKristen, Arnt VWixner, JonasDiemberger, IgorGonzalez-Moreno, JuanMaurer, Mathew SPlanté-Bordeneuve, ViolaineGarcia-Pavia, PabloTournev, IvailoGonzalez-Costello, JoseCariou, EveGonzález-Duarte, AlejandraGlass, OliverChapman, DougAmass, Leslie2023-09-052023-09-052023-07-17Amyloid. 2023 Jul 17;1-4.http://hdl.handle.net/20.500.12105/16408engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.Attribution-NonCommercial-NoDerivatives 4.0 Internacional37459334110.1080/13506129.2023.22294841744-2818Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosisopen access